Over the projection period, it is anticipated that the rising prevalence of spinal muscular atrophy (SMA) will fuel market expansion. For instance, according to the Spinal Muscular Atrophy Foundation, a nonprofit group whose goal is to hasten the development of a treatment for spinal muscular atrophy, SMA is one of the most prevalent uncommon disorders in the U.S., affecting between 10,000 and 25,000 children and adults. During the course of the projected period, a rise in new launches is anticipated to fuel market expansion.
The global Spinal Muscular Atrophy Market is estimated to be valued at US$ 1,600.6 million in 2022 and is expected to exhibit a CAGR of 13.3% during the forecast period (2022-2030).
Key Competitors in the Spinal Muscular Atrophy industry:
1. Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. In January, 2023 Biogen and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration agreement to develop Alcyone’s ThecaFlex DRx™ System, an implantable medical device intended for subcutaneous delivery of antisense oligonucleotide (ASO) therapies into the intrathecal space.
2. CYTOKINETICS
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. In May, 2022 Cytokinetics, Incorporated and The ALS Association today announced the continuation of their partnership in the fight against ALS.
3. F. Hoffmann-La Roche Ltd.
Roche Holding AG engages in the pharmaceuticals and diagnostics. The company was founded in 1896 and is headquartered in Basel, Switzerland.
4. Genentech, Inc.
Founded in 1976, Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients. The company has headquarters in South San Francisco, California.
5. PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
6. Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol.
7. Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California. In November, 2022 Ionis partners with Metagenomi to add gene editing to its broad technology platform.
8. Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company was founded in 1925 and is headquartered in Chuo, Japan.
9. Astellas Pharma Inc.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals in the Japan, United States, and internationally. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
*Definition- A hereditary condition known as spinal muscular atrophy causes the muscles used for movement to become weaker.
